4-(2,6-Diisopropylphenyl)-1,1-dimethylsemicarbazide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2,6-Diisopropylphenyl)-1,1-dimethylsemicarbazide
• 英文别名: 1-(dimethylamino)-3-[2,6-di(propan-2-yl)phenyl]urea
• 化学式: C₁₅H₂₅N₃O
• 分子量: 263.38
• InChiKey: OJXLPZILRBJYGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO
  申请人：The Regents of the University of Michigan

  公开号：US20220162160A1

  公开（公告）日：2022-05-26

  A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.